LivaNova (LIVN) Stock May Be Below Fair Value But Fair On Earnings

LivaNova has delivered a solid 46.7% return over the past three years, while a Discounted Cash Flow (DCF) intrinsic value estimate points to the stock trading at a sizable discount to that modelled value. At the same time, standard market multiples look roughly in line with peers, which leaves the stock looking cheaper on cash flow than on earnings benchmarks.

• A 46.7% return over three years suggests LivaNova shares have already rewarded patient investors, so any valuation edge now matters more.
• The company’s ability to convert its medical device portfolio into consistent free cash flow can support the current share price, while any setback in cash generation or higher capital needs may weaken the case.
• LivaNova screens as broadly cheap on a composite of checks, with a high value score of 5 that points to a stock that looks undervalued across most of the broader tests.

The issue now is whether that gap between the intrinsic value estimate and the current market price offers enough appeal once the cash flow assumptions and risks around LivaNova are weighed up.

Spot undervalued opportunities with similarly strong cash flow support by scanning our hand picked list of 45 high quality undervalued stocks while you assess where LivaNova fits in your portfolio.

Is LivaNova a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) model here uses LivaNova’s projected cash generation to estimate what the stock could be worth today. On the latest numbers, LivaNova produced trailing twelve month free cash flow of about $177.1 million, and the model assumes these cash flows grow over time rather than contract. Feeding those projections into a 2 Stage Free Cash Flow to Equity framework gives an intrinsic value estimate of about $141.64 per share.

Compared with the current share price, this outcome suggests the stock trades at roughly a 43.7% discount to that intrinsic value estimate. The key judgment for you as an investor is whether the assumed future growth in free cash flow is realistic for LivaNova given its medical device focus and capital needs.

On this DCF view, LivaNova stock currently screens as undervalued relative to its modelled cash flows.

Our Discounted Cash Flow (DCF) analysis suggests LivaNova is undervalued by 43.7%. Track this in your watchlist or portfolio, or discover 45 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for LivaNova.

Is LivaNova Fairly Priced on Earnings?

The P/E multiple is a useful cross check for LivaNova because it links the share price directly to the company’s reported earnings. LivaNova currently trades on a P/E of about 23.3x, which is below the Medical Equipment industry average of roughly 27.5x and also under the peer group average of about 30.1x.

A fair P/E ratio for LivaNova, based on its profile relative to peers, is estimated at around 24.3x. That sits only slightly above the current 23.3x level, so the market price is close to what this tailored benchmark would suggest. The P/E does not indicate a sharp discount or premium compared with comparable medical device companies, which is consistent with the picture from the broader checks.

On the earnings multiple, LivaNova stock appears roughly fairly valued compared with both its tailored fair P/E and its industry peers.

See what the numbers say about this price — find out in our valuation breakdown.

The LivaNova Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for LivaNova extend this valuation puzzle by spelling out which paths for LivaNova's growth, margins and earnings would need to play out for the stock to be worth materially more or less than today. These narratives sit on the company's Community page. Where a ratio or valuation model gives a single number, these narratives turn that into a clear set of future conditions that you can monitor over time.

LivaNova attracts sharply different views, with some investors focused on cardiopulmonary and epilepsy growth potential while others worry about supply and reimbursement constraints.

Bull case: 20% undervalued

"The rapid scaling of manufacturing capacity, expanded software-driven service models (notably, the PCBA/Essenz platform upgrades) and careful investments in IT and supply chain infrastructure offer strong operational leverage..."

Read the full Bull Case to see why LivaNova could be undervalued

Bear case: 6% overvalued

"While LivaNova is benefitting from a rapidly aging global population and rising chronic disease burden, giving a structural boost to the demand for cardiac and neurological devices, supply chain bottlenecks in cardiopulmonary consumables and dependence on third-party suppliers risk constraining the company's ability to meet surging demand..."

Read the full Bear Case to see why LivaNova could be overvalued

Do you think there's more to the story for LivaNova? Head over to our Community to see what others are saying!

The Bottom Line

The Discounted Cash Flow (DCF) work suggests LivaNova could be undervalued, while the P/E view points to a stock that is priced close to peer expectations. The high value checks indicate the broader balance of signals leans supportive, rather than pointing to a clear red flag. What really decides the outcome from here is whether LivaNova can keep turning its medical device portfolio into steady free cash flow without heavier than expected capital needs. That is the key distinction between the bull view of a mispriced opportunity and the bear view of a possible value trap.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com